Exhibit
10.15


EMPLOYMENT
AGREEMENT


THIS EXECUTIVE
EMPLOYMENT AGREEMENT (this “Agreement”) executed this     day of
March, 2007 and effective as of  the same
date, is by and between Isolagen, Inc., a Delaware corporation (together
with its subsidiaries, the “Company” or “Isolagen”), and Declan Daly, an
individual residing in  Ireland (the “Executive”).


W
I T N E S S E T H:


WHEREAS, the
Executive serves the Company as Executive
Vice President – Europe and Chief Financial Officer; and


WHEREAS, the
Company has employed Executive as its Executive
Vice President – Europe and Chief Financial Officer since June 5, 2006
and the Company and the Executive have not 
previously entered into an employment agreement that was contemplated at
the commencement of Executive’s employment by the Company, and now wish to do
so;


NOW THEREFORE in
consideration of the mutual benefits to be derived from this Agreement, the
Company and the Executive hereby agree as follows:


1.             Term
of Employment; Office and Duties.


(a)        Commencing
on June 5, 2006 (the “Employment Date”), and for an initial term ending
June 30, 2009 the Company shall employ the Executive as an executive of
the Company with the title of Executive Vice President - Europe and Chief
Financial Officer, with the duties and responsibilities prescribed for such
offices in the Bylaws of the Company and such additional duties and
responsibilities consistent with such positions as may from time to time be
assigned to the Executive by the Board of Directors.  Executive shall report to the Chief Executive
Officer and President.  Executive agrees
to perform such duties and discharge such responsibilities in accordance with
the terms of this Agreement.  This Agreement shall be renewed for an
additional one (1) year term, by the mutual written agreement of the
Executive and the Company at least thirty (30) days prior to its expiration.


(b)        The
Executive shall devote substantially all of his working time to the business
and affairs of the Company other than during vacations of four weeks per year
and periods of illness or incapacity; 
provided, however, that nothing in this Agreement shall preclude the
Executive from devoting time required:  (i) for serving as a director
or officer of any organization or entity not in a competing business with the
Company, and any other businesses in which the Company becomes involved;
(ii) delivering lectures or fulfilling speaking engagements; or
(iii) engaging in charitable and community activities provided  that such activities do not interfere with
the performance of his duties hereunder.


2.             Compensation
and Benefits.


For all services
rendered by the Executive in any capacity during the period of Executive’s
employment by the Company, including without limitation, services as an
executive officer or member of any committee of the Board of Directors or any
subsidiary, affiliate or division thereof, from and after the Effective Date,
the Executive shall be compensated as follows:


(a)           Base
Salary.  The Company shall pay the Executive a fixed salary (“Base Salary”)
at a rate of Three Hundred Sixty Eight Thousand Five Hundred Dollars ($368,500)
per year.  The Board of Directors may periodically review the Executive’s
Base Salary and may determine to increase (but not decrease) the Executive’s
salary, in accordance with such policies as the Company may hereafter adopt
from time to time, if it deems appropriate.  Base Salary will be payable
in accordance with the customary payroll practices of the Company.


(b)           Annual
Bonus.   Executive is entitled to
receive an annual bonus (the “Annual Bonus”), payable each year subsequent to
the issuance of final audited financial statements, but in no case later than
120 days after the end of the Company’s most recently completed fiscal
year.   The final determination on the
amount of the Annual Bonus will be made by the Compensation Committee of the
Board of Directors, based primarily on criteria













mutually agreed upon
between Executive and the Company’s CEO and approved by the Compensation
Committee, established with respect to the ensuing fiscal year, within thirty
(30) days following the adoption by the Board of Directors of a budget relating
to the ensuing year.  Criteria for the
Annual Bonus shall be agreed upon prior to or within sixty (60) days after the
execution of this Agreement.  The
Compensation Committee may also consider other more subjective factors in
making its determination.  The targeted
amount of the Annual Bonus shall be 50%, with up to 70%, of the Executive’s
base salary. The actual Annual Bonus for any given period may be higher or
lower than the target.  For any fiscal
year in which Executive is employed for less than the full year, Executive
shall receive a bonus which is prorated based on the number of full months in
the year which are worked.


(c)           Fringe
Benefits, Option Grants and Miscellaneous Employment Matters.


(i)            Executive
is entitled to participate in such disability, health and life insurance and
other fringe benefit plans or programs, including a Section 401(k)
retirement plan, of the Company established from time to time by the Board of
Directors, if any, to the extent that his position, tenure, salary, age, health
and other qualifications make him eligible to participate, subject to the
rules and regulations applicable thereto.  In addition, the Executive
shall be entitled to the following benefits:


(ii)           Contemporaneous
with commencement of his employment with the Company, the Executive was granted
a non-qualified stock option (the “Employment Option”) to purchase 325,000
shares of the Company’s Common Stock, par value $.001 per share (the “Common
Stock”) with an exercise price per share equal to the closing price of Isolagen
on the Employment Date. The term of the Employment Option will be for a period
of five (5) years from the date of grant and governed by the terms of an
Option Agreement between the Executive and the Company.  The shares
eligible for purchase under the Employment Option grant vest ratably, annually,
over the three years following the Employment Date.


(iii)          Notwithstanding
the provisions of paragraph (ii) hereinabove, the vesting of the Employment
Option shall accelerate and vest immediately upon a change in control of the
Company as defined in Rule 405 of the Securities Act of 1933.


(d)           Withholding
and Employment Tax.  Payment of all compensation hereunder shall be
subject to customary withholding tax and other employment taxes as may be
required with respect to compensation paid by an employer/corporation to an
employee.


(e)           Disability. 
The Company shall provide the Executive with a policy of disability insurance
benefits of at least sixty percent (60%) of his gross Base Salary per
month.   To the extent permitted by the
Company’s existing disability policy, the Executive’s disability policy will be
a portable policy.  The Executive agrees
to pay for any additional premium payments resulting from providing a portable
policy (in comparison to a group policy) and further agrees to have the
additional premium payments deducted from his pay.   In the event of the Executive’s Disability (as
hereinafter defined), the Executive and his family shall continue to be covered
by all of the Company’s life, medical, health and dental plans, at the Company’s
expense, to the extent such benefits can be obtained at a reasonable cost, for
the lesser of the term of such Disability (as hereinafter defined) or eighteen
(18) months, in accordance with the terms of such plans.


(f)            Death. 
The Company shall provide the Executive with a policy of term life insurance
benefits in the amount of at least One Million Dollars ($1,000,000). To the
extent permitted by the Company’s existing life insurance policy, the Executive’s
life insurance policy will be a portable policy.  The Executive agrees to pay for any
additional premium payments resulting from providing a portable policy (in
comparison to a group policy) and further agrees to have the additional premium
payments deducted from his pay.    In the
event of the Executive’s death, the Executive’s family shall continue to be
covered by all of the Company’s medical, health and dental plans, at the
Company’s expense, to the extent such benefits can be obtained at a reasonable
cost, for eighteen (18) months following the Executive’s death in accordance
with the terms of such plans.


(g)           Vacation. 
Executive shall receive four (4) weeks of vacation annually, administered
in accordance with the Company’s existing vacation policy.



 2
 









3.             Business
Expenses.


The Company shall
pay or reimburse all reasonable travel and entertainment expenses incurred by
the Executive in connection with the performance of his duties under this
Agreement, including such other travel as may be required or appropriate to
fulfill the responsibilities of his office, all in accordance with such
policies and procedures as the Company may from time to time establish for
senior officers and as required to preserve any deductions for federal income
taxation purposes to which the Company may be entitled and subject to the
Company’s normal requirements with respect to reporting and documentation of
such expenses.


4.             Termination
of Employment.


Notwithstanding
any other provision of this Agreement, Executive’s employment with the Company
may be terminated upon written notice to the other party as follows:


(a)           By
the Company, in the event of the Executive’s death or Disability (as
hereinafter defined) or for Cause (as hereinafter defined). For purposes of
this Agreement, “Cause” shall mean either: (i) the indictment of, or the
bringing of formal charges against, Executive by a governmental authority of
competent jurisdiction for charges involving criminal fraud or embezzlement;
(ii) the conviction of Executive of a crime involving an act or acts of
dishonesty, fraud or moral turpitude by the Executive, which act or acts
constitute a felony; (iii) Executive having willfully caused the Company,
without the approval of the Board of Directors, to fail to abide by either a
valid contract to which the Company is a party or the Company’s Bylaws;
(iv) Executive having committed acts or omissions constituting gross
negligence or willful misconduct with respect to the Company;
(v) Executive having committed acts or omissions constituting a material
breach of Executive’s duty of loyalty or fiduciary duty to the Company or any
material act of dishonesty or fraud with respect to the Company which are not
cured in a reasonable time, which time shall be 30 days from receipt of written
notice from the Company of such material breach; (vi) Executive having
committed acts or omissions constituting a material breach of this Agreement,
including any failure of the Executive to follow a directive from one or more
of his superiors, the Board of Directors and/or any Committee thereof; or
(vii) Executive having failed to meet agreed upon minimum performance
criteria.  A determination that Cause exists as defined in clauses (iv),
(v), (vi) or (vii) (as to this Agreement) of the preceding sentence
shall be made in good faith and by at least a majority of the members of the
Board of Directors.  For purposes of this Agreement, “Disability” shall mean
the inability of Executive, in the reasonable judgment of a physician appointed
by the Board of Directors, to perform his duties of employment for the Company
or any of its subsidiaries because of any physical or mental disability or
incapacity, where such disability shall exist for an aggregate period of more
than 120 days in any 365-day period or for any period of 90 consecutive
days.  The Company shall by written notice to the Executive specify the
event relied upon for termination pursuant to this Section 4(a), and
Executive’s employment hereunder shall be deemed terminated as of the date of
such notice.  In the event of any termination under this
Subsection 4(a), the Company shall pay all amounts then due to the
Executive under Section 2(a) of this Agreement for any portion of the
payroll period worked but for which payment had not yet been made up to the
date of termination, and, if such termination was for Cause, the Company shall
have no further obligations to Executive under this Agreement, and any and all
options granted hereunder shall terminate according to their terms.  In
the event of a termination due to Executive’s Disability or death, the Company
shall comply with its obligations under Sections 2(e) and 2(f).


(b)           By
the Company, in the absence of Cause, for any reason and in its sole and
absolute discretion, provided that in such event the Company shall, as
liquidated damages or severance pay, or both, continue to pay to Executive the
Base Salary (at a monthly rate equal to the rate in effect immediately prior to
such termination) for the lesser of the remaining term as defined above or six
months from the date of termination (the “Termination Payments”), when, as and
if such payments would have been made in the absence of Executive’s termination.


(c)           In
the event that any amounts payable and/or any benefits provided to the
Executive under the terms of this Agreement and/or under any other plan,
agreement or arrangement by which he is to receive payments or benefits in the
nature of compensation would constitute “excess parachute payments” as that
term is defined for purposes of Section 280G of the Internal Revenue Code of
1986, as amended (“Code”) and Treasury Regulations promulgated pursuant
thereto, then the amounts payable under the terms of this Agreement and/or
under any other plan, agreement or arrangement shall be reduced so that no
payments are deemed “excess parachute



 3
 









payments.”  Any decisions
regarding this requirement or implementation of reductions shall be made by tax
counsel selected by the Company.


(d)           If
any payment to Executive under the terms of this Agreement is determined to
constitute a payment of nonqualified deferred compensation for purposes of
Section 409A of the Code, such payment shall be delayed until the date that is
six months after the date of Executive’s separation from service with the
Company, so as to comply with the special rule for certain “specified employees”
set forth in Code Section 409A(a)(2)(B)(i) unless it is determined that
immediate distribution is permissible (and does not trigger any additional tax
liability pursuant to Code Section 409A(a)(l)) pursuant to Code Section
409A(a)(2)(A)(v) by reason of being payable in connection with a change in the
ownership or effective control of the Company or in the ownership of a
substantial position of the assets of the Company.


5.             Non-Competition.


During the period
of Executive’s employment hereunder and during the period, if any, during which
payments are required to be made to the Executive by the Company pursuant to
Sections 4(a) or 4(b), the Executive shall not, within any state or
foreign jurisdiction in which the Company or any subsidiary of the Company is
then providing services or products or marketing its services or products (or
engaged in active discussions to provide such services), or within a one
hundred (100) mile radius of any such state or foreign jurisdiction, directly
or indirectly own any interest in, manage, control, participate in, consult
with, render services for, or in any manner engage in any business engaged in
by the Company (unless the Board of Directors shall have authorized such
activity and the Company shall have consented thereto in writing).  The term “business engaged in by the Company”
shall mean the development and commercialization of autologous fibroblast
system technology for application in, among other therapies, dermatology,
surgical and post-traumatic scarring, skin ulcers, cosmetic surgery,
periodontal disease, reconstructive dentistry, vocal chord injuries, urinary
incontinence, and digestive and gastroenterological disorders and other
applications relating to the market for autologous fibroblast or UMC cells and
the five derivative cell lines: osteoblast, chondroblast, fibroblast,
adipocyte, and neuroectoderm.  Investments of less than five percent of
the outstanding securities of any class of a corporation subject to the
reporting requirements of Section 13 or Section 15(d) of the
Securities Exchange Act of 1934, as amended, shall not be prohibited by this
Section 5. Executive’s obligations under this Section 5 arising after
the termination of Executive shall be suspended during any period in which the
Company fails to pay to him Termination Payments required to be paid to him
pursuant to this Agreement.  The provisions of this Section 5 are
subject to the provisions of Section 14 of this Agreement.


6.             Inventions
and Confidential Information.


The parties hereto
recognize that a major need of the Company is to preserve its specialized
knowledge, trade secrets, and confidential information.  The strength and
good will of the Company is derived from the specialized knowledge, trade
secrets, and confidential information generated from experience with the
activities undertaken by the Company and its subsidiaries.  The disclosure
of this information and knowledge to competitors would be beneficial to them
and detrimental to the Company, as would the disclosure of information about
the marketing practices, pricing practices, costs, profit margins, design
specifications, analytical techniques, and similar items of the Company and its
subsidiaries.  The Executive acknowledges that the proprietary
information, observations and data obtained by him while employed by the
Company concerning the business or affairs of the Company are the property of
the Company.  By reason of his being a senior executive of the Company,
the Executive has or will have access to, and has obtained or will obtain,
specialized knowledge, trade secrets and confidential information about the
Company’s operations and the operations of its subsidiaries, which operations
extend throughout the United States and in foreign jurisdictions.  (For
purposes of this Section 6, “Company” shall mean the Company and each of
its controlled subsidiaries.)  Therefore, subject to the provisions of
Section 14 hereof, the Executive hereby agrees as follows, recognizing
that the Company is relying on these agreements in entering into this
Agreement:


(i)            The
Executive will not use, disclose to others, or publish or otherwise make
available to any other party any inventions or any confidential business
information about the affairs of the Company, including but not limited to
confidential information concerning the Company’s products, methods,
engineering designs and standards, analytical techniques, technical
information, customer information, employee



 4
 









information, and other
confidential information acquired by him in the course of his past or future
services for the Company.  Executive agrees to hold as the Company’s
property all books, papers, letters, formulas, memoranda, notes, plans,
records, reports, computer tapes, printouts, software and other documents, and
all copies thereof and therefrom, in any way relating to the Company’s business
and affairs, whether made by him or otherwise coming into his possession, and
on termination of his employment, or on demand of the Company, at any time, to
deliver the same to the Company within twenty four (24) hours of such
termination or demand.


(ii)           During
the period of Executive’s employment with the Company and for eighteen (18)
months thereafter, (a) the Executive will not directly or indirectly
through another entity induce or otherwise attempt to influence any employee of
the Company to leave the Company’s employ and (b) the Executive will not
directly or indirectly hire or cause to be hired or induce a third party to
hire, any such employee (unless the Board of Directors shall have authorized
such employment and the Company shall have consented thereto in writing) or in
any way interfere with the relationship between the Company and any employee
thereof and (c) induce or attempt to induce any customer, supplier,
licensee, licensor or other business relation of the Company to cease doing
business with the Company or in any way interfere with the relationship between
any such customer, supplier, licensee or business relation of the Company.


7.             Indemnification.


The Company will
indemnify (and advance the costs of defense of) the Executive (and his legal
representatives) to the fullest extent required by the laws of the state in
which the Company is incorporated, as in effect at the time of the subject act
or omission, or by the Certificate of Incorporation and Bylaws of the Company,
as in effect at such time or on the date of this Agreement, whichever affords
greater protection to the Executive, and the Executive shall be entitled to the
protection of any insurance policies the Company may elect to maintain
generally for the benefit of its executive officers, against all judgments,
damages, liabilities, costs, charges and expenses whatsoever incurred or
sustained by him or his legal representative in connection with any action,
suit or proceeding to which he (or his legal representatives or other
successors) may be made a party by reason of his being or having been an
officer of the Company or any of its subsidiaries except that the Company shall
have no obligation to indemnify Executive for liabilities resulting from
conduct of the Executive with respect to which a court of competent
jurisdiction has made a final determination that Executive committed gross
negligence or willful misconduct.


8.             Litigation
Expenses.


In the event of
any litigation or other proceeding between the Company and the Executive with
respect to the subject matter of this Agreement and the enforcement of the
rights hereunder and such litigation or proceeding results in final judgment or
order in favor of the Executive, which judgment or order is substantially
inconsistent with the positions asserted by the Company in such litigation or
proceeding, the losing party shall reimburse the prevailing party for all of
his/its reasonable costs and expenses relating to such litigation or other
proceeding, including, without limitation, his/its reasonable attorneys’ fees
and expenses.


 9.            Consolidation;
Merger; Sale of Assets; Change of Control.


Nothing in this
Agreement shall preclude the Company from combining, consolidating or merging
with or into, transferring all or substantially all of its assets to, or
entering into a partnership or joint venture with, another corporation or other
entity, or effecting any other kind of corporate combination provided that the
corporation resulting from or surviving such combination, consolidation or
merger, or to which such assets are transferred, or such partnership or joint
venture assumes this Agreement and all obligations and undertakings of the
Company hereunder. Upon such a consolidation, merger, transfer of assets or
formation of such partnership or joint venture, this Agreement shall inure to the
benefit of, be assumed by, and be binding upon such resulting or surviving
transferee corporation or such partnership or joint venture, and the term “Company,”
as used in this Agreement, shall mean such corporation, partnership or joint
venture or other entity, and this Agreement shall continue in full force and
effect and shall entitle the Executive and his heirs, beneficiaries and
representatives to exactly the same compensation, benefits, perquisites,
payments and other rights as would have been their entitlement had such
combination, consolidation, merger, transfer of assets or formation of such
partnership or joint venture not occurred.



 5
 









10.           Survival
of Obligations.


Sections 4, 5, 6,
7, 8, 9, 11, 12 and 14 shall survive the termination for any reason of this
Agreement (whether such termination is by the Company, by the Executive, upon
the expiration of this Agreement or otherwise).


11.           Executive’s
Representations.


The Executive
hereby represents and warrants to the Company that (i) the execution,
delivery and performance of this Agreement by the Executive do not and shall
not conflict with, breach, violate or cause a default under any contract,
agreement, instrument, order, judgment or decree to which the Executive is a
party or by which he is bound, (ii) the Executive is not a party to or
bound by any employment agreement, non-compete agreement or confidentiality
agreement with any other person or entity and (iii) upon the execution and
delivery of this Agreement by the Company, this Agreement shall be the valid
and binding obligation of the Executive, enforceable in accordance with its
terms.  The Executive hereby acknowledges and represents that he has
consulted with legal counsel regarding his rights and obligations under this
Agreement and that he fully understands the terms and conditions contained
herein.


12.           Company’s
Representations.


The Company hereby
represents and warrants to the Executive that (i) the execution, delivery
and performance of this Agreement by the Company do not and shall not conflict
with, breach, violate or cause a default under any contract, agreement,
instrument, order, judgment or decree to which the Company is a party or by
which it is bound and (ii) upon the execution and delivery of this
Agreement by the Executive, this Agreement shall be the valid and binding
obligation of the Company, enforceable in accordance with its terms.


13.           Enforcement.


Because the
Executive’s services are unique and because the Executive has access to
confidential information concerning the Company, the parties hereto agree that
money damages would not be an adequate remedy for any breach of this
Agreement.  Therefore, in the event of a breach or threatened breach of
this Agreement, the Company may, in addition to other rights and remedies existing
in its favor, apply to any court of competent jurisdiction for specific
performance and/or injunctive or other relief in order to enforce, or prevent
any violations of, the provisions hereof (without posting a bond or other
security).


14.           Severability.


In case any one or
more of the provisions or part of a provision contained in this Agreement shall
for any reason be held to be invalid, illegal or unenforceable in any respect
in any jurisdiction, such invalidity, illegality or unenforceability shall be
deemed not to affect any other jurisdiction or any other provision or part of a
provision of this Agreement, nor shall such invalidity, illegality or
unenforceability affect the validity, legality or enforceability of this
Agreement or any provision or provisions hereof in any other jurisdiction; and
this Agreement shall be reformed and construed in such jurisdiction as if such
provision or part of a provision held to be invalid or illegal or unenforceable
had never been contained herein and such provision or part reformed so that it
would be valid, legal and enforceable in such jurisdiction to the maximum
extent possible.  In furtherance and not in limitation of the foregoing,
the Company and the Executive each intend that the covenants contained in Sections
5 and 6 shall be deemed to be a series of separate covenants, one for each
county of the Commonwealth of Pennsylvania and one for each and every other
state, territory or jurisdiction of the United States and any foreign country
set forth therein.  If, in any judicial proceeding, a court shall refuse
to enforce any of such separate covenants, then such unenforceable covenants
shall be deemed eliminated from the provisions hereof for the purpose of such
proceedings to the extent necessary to permit the remaining separate covenants
to be enforced in such proceedings.  If, in any judicial proceeding, a
court shall refuse to enforce any one or more of such separate covenants
because the total time, scope or area thereof is deemed to be excessive or
unreasonable, then it is the intent of the parties hereto that such covenants,
which would otherwise be unenforceable due to such excessive or unreasonable
period of time, scope or area, be enforced for such lesser period of time,
scope or area as shall be deemed reasonable and not excessive by such court.



 6
 









15.           Entire
Agreement; Amendment.


Except as
otherwise set forth in this Agreement, this Agreement contains the entire
agreement between the Company and the Executive with respect to the subject
matter hereof and thereof.  This Agreement may not be amended, waived,
changed, modified or discharged except by an instrument in writing executed by
or on behalf of the party against whom enforcement of any amendment, waiver,
change, modification or discharge is sought.  No course of conduct or
dealing shall be construed to modify, amend or otherwise affect any of the
provisions hereof.


16.           Notices.


All notices,
requests, demands and other communications hereunder shall be in writing and
shall be deemed to have been duly given if physically delivered, delivered by
express mail or other expedited service or upon receipt if mailed, postage
prepaid, via registered mail, return receipt requested, addressed as follows:


To the Company:


Isolagen, Inc.


405 Eagleview Blvd.


Exton, Pennsylvania 19341


Attention: Susan
Ciallella


To the Executive:


Declan Daly


[ADDRESS]


[CITY, STATE, ZIP]


Ireland


 and/or to such
other persons and addresses as any party shall have specified in writing to the
other.



 7
 









17.           Assignability.


This Agreement
shall not be assignable by either party and shall be binding upon, and shall
inure to the benefit of, the heirs, executors, administrators, legal
representatives, successors and assigns of the parties.  In the event that
all or substantially all of the business of the Company is sold or transferred,
then this Agreement shall be binding on the transferee of the business of the
Company whether or not this Agreement is expressly assigned to the transferee.


18.           Governing
Law.


This Agreement
shall be governed by and construed under the laws of the Commonwealth of
Pennsylvania.


19.           Waiver
and Further Agreement.


Any waiver of any
breach of any terms or conditions of this Agreement shall not operate as a
waiver of any other breach of such terms or conditions or any other term or condition,
nor shall any failure to enforce any provision hereof operate as a waiver of
such provision or of any other provision hereof.  Each of the parties
hereto agrees to execute all such further instruments and documents and to take
all such further action as the other party may reasonably require in order to
effectuate the terms and purposes of this Agreement.


20.           Headings
of No Effect.


The paragraph
headings contained in this Agreement are for reference purposes only and shall
not in any way affect the meaning or interpretation of this Agreement.


IN WITNESS
WHEREOF, the parties hereto have executed this Employment Agreement as of the
date first above written.


	
   

  	
  COMPANY:

  
	
   

  	
   

  
	
   

  	
  ISOLAGEN, INC.

  
	
   

  	
   

  
	
   

  	
  /s/ Ralph V. De
  Martino

  	
   

  
	
   

  	
  By: Ralph V. De
  Martino,

  
	
   

  	
   

  
	
   

  	
   

  	
  at the direction
  of the Board of Directors

  
	
   

  	
   

  
	
   

  	
  EXECUTIVE:

  
	
   

  	
   

  
	
   

  	
  /s/ Declan Daly

  	
   

  
	
   

  	
  Declan Daly

  
				



 



 8